These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
153 related items for PubMed ID: 2309157
1. 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the rat: characterization and age-dependent effects. Jarvis MF, Wagner GC. Synapse; 1990; 5(2):104-12. PubMed ID: 2309157 [Abstract] [Full Text] [Related]
2. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease. Jenner P, Marsden CD. J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760 [Abstract] [Full Text] [Related]
3. Age-dependent effects of the 2'-methyl analog of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine: prevention by inhibitors of monoamine oxidase B. Finnegan KT, Irwin I, Delanney LE, Langston JW. J Pharmacol Exp Ther; 1995 May; 273(2):716-20. PubMed ID: 7752075 [Abstract] [Full Text] [Related]
4. 2'-NH(2)-MPTP [1-methyl-4-(2'-aminophenyl)-1,2,3,6-tetrahydropyridine] depletes serotonin and norepinephrine in rats: a comparison with 2'-CH(3)-MPTP [1-methyl-4-(2'-methylphenyl)-1,2,3,6-tetrahydropyridine]. Unger EL, Mazzola-Pomietto P, Murphy DL, Andrews AM. J Pharmacol Exp Ther; 2002 Nov; 303(2):527-33. PubMed ID: 12388632 [Abstract] [Full Text] [Related]
5. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. Gal S, Zheng H, Fridkin M, Youdim MB. J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414 [Abstract] [Full Text] [Related]
6. Inhibition of types A and B monoamine oxidase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Fuller RW, Hemrick-Luecke SK. J Pharmacol Exp Ther; 1985 Mar; 232(3):696-701. PubMed ID: 3871853 [Abstract] [Full Text] [Related]
8. Neurotoxicity studies with the monoamine oxidase B substrate 1-methyl-3-phenyl-3-pyrroline. Ogunrombi MO, Malan SF, Terre'Blanche G, Castagnoli K, Castagnoli N, Bergh JJ, Petzer JP. Life Sci; 2007 Jul 19; 81(6):458-67. PubMed ID: 17655878 [Abstract] [Full Text] [Related]
9. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: Systemic administration. Giovanni A, Sieber BA, Heikkila RE, Sonsalla PK. J Pharmacol Exp Ther; 1994 Sep 19; 270(3):1000-7. PubMed ID: 7932147 [Abstract] [Full Text] [Related]
10. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Dluzen DE. Brain Res; 1996 Apr 09; 715(1-2):113-8. PubMed ID: 8739629 [Abstract] [Full Text] [Related]
11. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction]. Nishi K, Kondo T, Narabayashi H. No To Shinkei; 1987 Jul 09; 39(7):663-72. PubMed ID: 3314916 [Abstract] [Full Text] [Related]
12. CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo. Saporito MS, Brown EM, Miller MS, Carswell S. J Pharmacol Exp Ther; 1999 Feb 09; 288(2):421-7. PubMed ID: 9918541 [Abstract] [Full Text] [Related]
13. MPTP-induced oxidative stress and neurotoxicity are age-dependent: evidence from measures of reactive oxygen species and striatal dopamine levels. Ali SF, David SN, Newport GD, Cadet JL, Slikker W. Synapse; 1994 Sep 09; 18(1):27-34. PubMed ID: 7825121 [Abstract] [Full Text] [Related]
14. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Mounayar S, Boulet S, Tandé D, Jan C, Pessiglione M, Hirsch EC, Féger J, Savasta M, François C, Tremblay L. Brain; 2007 Nov 09; 130(Pt 11):2898-914. PubMed ID: 17855373 [Abstract] [Full Text] [Related]
15. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals. Andrews AM, Ladenheim B, Epstein CJ, Cadet JL, Murphy DL. Mol Pharmacol; 1996 Dec 09; 50(6):1511-9. PubMed ID: 8967972 [Abstract] [Full Text] [Related]
16. In brown Norway rats, MPP+ is accumulated in the nigrostriatal dopaminergic terminals but it is not neurotoxic: a model of natural resistance to MPTP toxicity. Zuddas A, Fascetti F, Corsini GU, Piccardi MP. Exp Neurol; 1994 May 09; 127(1):54-61. PubMed ID: 8200437 [Abstract] [Full Text] [Related]
19. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains. Haobam R, Sindhu KM, Chandra G, Mohanakumar KP. Behav Brain Res; 2005 Sep 08; 163(2):159-67. PubMed ID: 15941598 [Abstract] [Full Text] [Related]
20. FGF-2 in the MPTP model of Parkinson's disease: effects on astroglial cells. Otto D, Unsicker K. Glia; 1994 May 08; 11(1):47-56. PubMed ID: 8070894 [Abstract] [Full Text] [Related] Page: [Next] [New Search]